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Prostate apoptosis response-4 (Par-4) is a proapop-
totic protein with intracellular functions in the cyto-
plasm and nucleus. Unexpectedly, we noted Par-4
protein is spontaneously secreted by normal and
cancer cells in culture, and by Par-4 transgenic
mice that are resistant to spontaneous tumors. Short
exposure to endoplasmic reticulum (ER) stress-
inducing agents further increased cellular secretion
ofPar-4byabrefeldinA-sensitivepathway.Secretion
occurred independently of caspase activation and
apoptosis. Interestingly, extracellular Par-4 induced
apoptosis by binding to the stress response protein,
glucose-regulated protein-78 (GRP78), expressed at
the surface of cancer cells. The interaction of extra-
cellular Par-4 andcell surfaceGRP78 led toapoptosis
via ER stress and activation of the FADD/caspase-8/
caspase-3 pathway. Moreover, apoptosis inducible
by TRAIL, which also exerts cancer cell-specific
effects, is dependent on extracellular Par-4 signaling
via cell surface GRP78. Thus, Par-4 activates an
extrinsic pathway involving cell surface GRP78
receptor for induction of apoptosis.
INTRODUCTION
Prostate apoptosis response-4 (Par-4) is a leucine zipper domain
protein identified in cells undergoing apoptosis in response to
exogenous insults (Sells et al., 1994). Par-4 is expressed ubiqui-
tously among the various tissue types, and resides in both the
cytoplasm and the nucleus (Sells et al., 1997; El-Guendy et al.,
2003). Although endogenous Par-4 is largely inactivated, and
does not produce extensive apoptosis by itself, it is essential
for the apoptotic function of diverse cytotoxic agents (Gurumur-
thy et al., 2005). Interestingly, Par-4 overexpression is sufficientto induce apoptosis in most cancer cells, but not in normal or
immortalized cells, and this apoptotic action of Par-4 does not
require its leucine zipper domain (El-Guendy et al., 2003). Dele-
tion analyses have identified the core domain (aa137–195) of
Par-4, designated SAC (selective for apoptosis in cancer cells),
as the effector domain of Par-4. Like Par-4, the SAC domain
is capable of nuclear entry, caspase activation, inhibition of
NF-kB activity, and induction of apoptosis. The SAC domain is
100% conserved in rat, mouse, and human Par-4, and does
not resemble other proapoptotic proteins (El-Guendy et al.,
2003). Transgenic mice ubiquitously expressing the SAC domain
of Par-4 are resistant to the growth of spontaneous and inducible
tumors (Zhao et al., 2007). Consistent with its tumor suppressor
function in mice (Garcia-Cao et al., 2003), Par-4 is mutated or
silenced in endometrial cancer (Moreno-Bueno et al., 2007),
downregulated in renal cell carcinoma (Cook et al., 1999), and
in a nonfunctional state in prostate cancer due to inactivation
by the cell survival kinase, Akt1 (Goswami et al., 2005). Our
recent studies suggest Par-4 serves as an intracellular repressor
of topoisomerase 1 (TOP1) catalytic activity, and regulates DNA
topology to suppress cellular transformation by a SAC domain-
independent mechanism (Goswami et al., 2008).
Par-4- and SAC-Mediated Apoptosis
All Par-4 studies thus far have analyzed the role of intracellular
(i.e., cytoplasmic or nuclear) Par-4. Distinct partner proteins of
intracellular Par-4 have been confirmed, including zPKC (Diaz-
Meco et al., 1996), WT1 (Johnstone et al., 1996, ZIP kinase
(Page et al., 1999), Akt1 (Goswami et al., 2005), and TOP1 (Gos-
wami et al., 2008); each of these partner interactions requires the
leucine zipper domain. Par-4 interactions with zPKC or TOP1 in
the cytoplasm or nucleus, respectively, impede NF-kB activity
(Diaz-Meco et al., 1996; Goswami et al., 2008), and Par-4 inter-
actions with WT1 inhibit the Bcl-2 promoter (Cheema et al.,
2003); these interactions reveal distinct, cell compartment-
specific roles for the Par-4 partners in growth regulation.
Rather unexpectedly, our recent studies suggest Par-4 and
SAC domain are secreted by both normal/immortalized andCell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc. 377
Figure 1. Par-4 and the SAC Protein Are Secreted and Induce Apoptosis
(A) Bystander effect of Par-4 and SAC domain. PC-3 cells were transiently transfected with the indicated expression constructs, and subjected to ICC for active
caspase-3 to detect apoptosis, and counterstained with DAPI (right panel). Quantification of apoptosis in transfected (T) and nontransfected (NT) cells is
presented (left panel).
(B) Conditioned medium (CM) from transfected cells contains secreted Par-4-GFP and SAC-GFP protein. The CM from cells transfected with the indicated
expression constructs or pCB6+ vector was subjected to western blot (WB) analysis with the Par-4, ERK1/2, or actin antibody. Appropriate whole-cell extracts
(WCE) were used as controls.
(C) The secreted fusion proteins induce apoptosis in target PC-3 cells. Cells were treated with the CM from the indicated PC-3 transfectants (GFP, Par-4-GFP, or
SAC-GFP) or with the CM that was preincubated for 30minwith neutralizing antibody (Ab) for GFP, Par-4, or PTEN. After 24 hr, the cells were scored for apoptosis
by caspase-3 activation using ICC analysis.378 Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc.
cancer cells, and that these secreted proteins selectively inhibit
the growth of cancer cells. We have identified a regulatory loop
that involves the interaction of extracellular Par-4, via its SAC
domain, with the cell surface receptor GRP78, and that is depen-
dent on intracellular Par-4 in order to selectively induce
apoptosis in cancer cells.
RESULTS
Par-4 Is Secreted and InducesApoptosis of CancerCells
via Its SAC Domain
Although ectopic Par-4 and its SAC domain are well-known to
exert their apoptotic effects in the nucleus of the cell in which
they are produced, we have noted bystander activity in tumor
regression studies wherein a single intratumoral injection of an
adenoviral-Par-4 construct (with a 50%–60% transduction effi-
ciency) resulted in apoptosis in over 80% cells of the tumor
(Chakraborty et al., 2001). To further characterize this bystander
effect of Par-4, we transfected PC-3 cells in culture with GFP,
Par-4-GFP, or SAC-GFP expression constructs, and subjected
the cell populations to immunocytochemical (ICC) analysis for
active caspase-3 to detect apoptosis. Intriguingly, apoptosis
occurred not only in the green fluorescent Par-4-GFP or SAC-
GFP transfectants, but also in neighboring cells that did not
express the green-fluorescent Par-4-GFP protein (Figure 1A,
right panel). Quantification of the cultures for apoptotic cells indi-
cated a significantly large number of nontransfected cells under-
went apoptosis with Par-4-GFP or SAC-GFP transfection, but
not with the GFP construct (Figure 1A, left panel).
Further studies revealed the conditionedmedium (CM) derived
from Par-4-GFP-or SAC-GFP-transfected PC-3 and BPH-1 cells
contained Par-4-GFP and SAC-GFP proteins, respectively (Fig-
ure 1B). The CM did not contain detectable levels of actin or
ERK1/2 (Figure 1B), implying the GFP fusion proteins are not
released as a result of apoptotic cell death. Significantly, CM
fromtheGFP (control) andSAC-GFP transfectantsalsocontained
endogenous Par-4 (Figure 1B), indicating endogenous Par-4 is
secreted by PC-3 cells. Moreover, immortalized, nontransformed
BPH-1 cells, which do not undergo apoptosis with ectopic Par-4,
were transfectedwith either a pCB6+/Par-4 construct (lacking the
GFP-tag) or aGFPcontrol construct. CM from these cells showed
secretion of both endogenous Par-4 and ectopic Par-4 (Fig-
ure 1B), demonstrating secretion of Par-4 is neither dependent
on the GFP-tag, nor on apoptosis of the transfectants. Secretion
of endogenous Par-4 was not limited to prostatic cells; immortal-
ized human embryonic lung fibroblasts HEL, human embryonic
kidney epithelial cells HEK293, and mouse fibroblasts NIH 3T3
showed secretion of Par-4 (see Figure S1A available with this
article online). Overall, mammalian cells secrete endogenous
Par-4, as well as ectopic Par-4 and SAC protein.
To determine whether secreted Par-4 was functionally active,
PC-3 cells and BPH-1 cells were treated with the CM prepared
from PC-3 transfectants, and their response was examined byICC for caspase-3 activation. As seen in Figure 1C, the CM
from the Par-4-GFP and SAC-GFP transfectants (but not from
the GFP control transfectants) induced apoptosis in PC-3 cells,
but not in the BPH-1 cells. Importantly, when the CM was prein-
cubated with neutralizing antibodies for GFP, Par-4, or PTEN
(control), the apoptotic activity in the CM was neutralized by
antibodies against Par-4/SAC and the GFP-tag, but not by the
control PTEN antibody.
Because CM may contain other mammalian cell secreted
proteins, we used recombinant Par-4 and SAC (TRX-Par-4 and
TRX-SAC, respectively) as an alternate approach to determine
whether extracellular Par-4 and SAC induce apoptosis. Expo-
sure of PC-3 cells to TRX-Par-4 and TRX-SAC, but not TRX
control protein, produced apoptosis in a dose- and time-depen-
dent manner (Figure S1). When cancer cells PC-3, H460, and
HeLa were treated with these proteins and scored for apoptosis,
we noted that TRX-Par-4 and TRX-SAC, but not TRX, induced
apoptosis in each cell line (Figure 1D). Conversely, TRX-Par-4
or TRX-SAC did not induce apoptosis in the nontransformed
cells BPH-1 (Figure 1D). Indeed, TRX-Par-4 and TRX-SAC
induced apoptosis in diverse other cancer cell lines, but not non-
transformed cell lines (data not shown). We conclude recombi-
nant Par-4 is competent to cause apoptosis in diverse cancer
cell lines, and that the SAC domain of Par-4 is sufficient to
support apoptosis.
Par-4 Secretion Occurs by a BFA-Sensitive Pathway
and Is Not Dependent on Apoptosis
We also examined whether treatment of cells with proapoptotic
proteins, such as TRAIL, potentiated the secretion of endogenous
Par-4. PC-3 cells were treated with TRAIL for short time intervals
(30-180 min), which were of insufficient duration to produce
apoptosis, and the harvested CM and whole-cell lysates were
subjected to western blot analysis for endogenous Par-4 and
actin. TRAIL did not increase the levels of intracellular Par-4 in
the cell lysates, yet caused increased secretion of Par-4 in the
CM (Figure 2A). To determine whether Par-4 is released via the
conventional cell secretory pathway,we inhibited secretory trans-
port with brefeldin A (BFA), which blocks anterograde ER export
to the Golgi resulting in obstruction of secretion. Following
pretreatment with BFA, TRAIL caused a negligible increase in
Par-4 in the CM, yet the amount of intracellular Par-4 was unal-
tered (Figure 2A). As BFA blocks protein trafficking from the ER
to the Golgi, a characteristic step in cell secretion by the classical
pathway, these data indicate secretion of endogenous Par-4
occurredby theclassical pathway involving theER-Golgi network.
We also determined whether Par-4 secretion in the pres-
ence of TRAIL was associated with activation of apoptosis.
PC-3/DN-FADD cells stably expressing dominant-negative
FADD, which inhibits TRAIL-inducible apoptosis, were treated
with TRAIL for short time interval (Figure 2A). As seen in Fig-
ure 2A, TRAIL-induced Par-4 secretion in these cells. These find-
ings confirm secretion of Par-4 is not dependent on apoptosis.(D) Recombinant Par-4 and SAC protein induce apoptosis in cancer cells. Recombinant protein was subjected to SDS-PAGE and Coomassie blue (CB) staining
(left panel). Various cancer or nontransformed cells were treated with 100 nM amounts of each protein for 24 hr (right panel). The cells were scored for apoptosis
by ICC for active caspase-3. Panels C & D: Mean values (+ standard deviation bars) of three separate experiments are shown. Asterisk (*) indicates the difference
is statistically significant (p < 0.001) by the Student’s t test.Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc. 379
Par-4 Secretion Is Associated with ER Stress
As Par-4 induction is not dependent on apoptosis, we examined
whether secretion of Par-4 is a cellular response to ER-stress.
PC-3 cells were treated with prototypical inducers of ER-stress
(Marchand et al., 2006), such as thapsigargin (TG; an inhibitor
of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase) and tuni-
camycin (TU; an inhibitor of N-linked glycosylation), for short
time intervals, and CMprepared from the cultures was examined
for secreted Par-4 protein. As seen in Figure 2B (upper panel), TG
and TU induced Par-4 secretion, which was severely attenuated
by the presence of BFA. To confirm induction of ER-stress, PC-3
cells were treated with TG, TU, or TRAIL for short time intervals,
and upregulation of GRP78 and CHOP/GADD153, key indicators
of ER-stress was examined. As seen in Figure 2B, TG, TU, and
Figure 2. Par-4 Protein Is Secreted by an
ER-Stress Inducible Pathway
(A) Par-4 protein is secreted by a BFA-sensitive
pathway independently of apoptosis. Cells were
left untreated or pretreated with BFA (1 mM)
for 30 min as indicated, then exposed to TRAIL
(100 ng/ml) for 30, 60, and 180 min. Whole-cell
extracts (WCE) or CM were prepared, and sub-
jected to western blot (WB) analysis for Par-4 or
actin. The CM was also subjected to SDS-PAGE
followed byCoomassie blue (CB) staining to reveal
the 68 kDa BSA band for loading control (upper
panels and lower left panel). PC-3 or PC-3/DN-
FADD cells were also treated with TRAIL or left
untreated (UT) for 24 hr, and scored for apoptosis
by ICC for active caspase 3 (lower right panel).
Mean values (+ standard deviation bars) of three
separate experiments are shown. Asterisk (*) indi-
cates the difference is statistically significant (p <
0.001) by the Student’s t test.
(B) Par-4 protein is secreted by an ER-stress
inducible pathway. PC-3 cells were left untreated
(UT) or treated with thapsigargin (TG,100 nM) or
tunicamycin (TU, 5 mM) in the presence or absence
of BFA (1 mM) for the indicated time intervals. CM
was prepared, and subjected to SDS-PAGE fol-
lowed by staining with Coomassie blue (CB; upper
panel). Also, whole-cell extracts from untreated
(UT) PC-3 cells or PC-3 cells treated with vehicle,
TG, TU, or TRAIL for various time intervals were
subjected to western blot (WB) analysis for Par-
4, GRP78, and actin (middle panel), or CHOP/
GADD153 and actin (lower panel).
TRAIL increased expression of intracel-
lular GRP78 and CHOP/GADD153 rela-
tive to untreated cells. As a whole, these
findings imply secretion of Par-4 is asso-
ciated with induction of ER-stress.
Par-4 and SAC Bind to GRP78
To determine whether Par-4 induces
apoptosis by binding to specific proteins,
we performed GST-pull down assays on
whole cell extracts from PC-3 cells, using
either GST-Par-4 or GST as bait. GST-
Par-4, but not GST, bound a number of proteins, andmass spec-
trometry identified the 80 kDa band (Figure S2A) as GRP78
(mass spectrometry data are shown in Figure S2C and Table
S1). GRP8 is a typical stress protein that is a member of the
HSP70 superfamily of heat shock proteins (Lee, 2007). For veri-
fication, the proteins pulled down from the PC-3 lysates were
subjected to western blot analysis for GRP78; His-SAC-GFP,
but not the His-GFP control, pulled down GRP78 protein from
PC-3 cells (Figure S2B).
Seeking confirmation that endogenous GRP78 binds Par-4 in
mammalian cells, we used PC-3 whole-cell lysates for coimmu-
noprecipitations with GFP, Par-4, or GRP78 antibodies, followed
by immunoblotting for Par-4 or GRP78. The data demonstrate
Par-4 antibody coimmunoprecipitated GRP78, and the GRP78380 Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc.
antibody coimmunoprecipitated Par-4 (Figure 3A), whereas the
GFP antibody coimmunoprecipitated neither Par-4 nor GRP78.
These findings indicate endogenous Par-4 is bound to GRP78
protein.
Although the above data indicate Par-4 binds GRP78, it was
unclear if the SAC domain and GRP78 interact in the same
manner. We transfected PC-3 cells with GFP, Par-4-GFP, or
SAC-GFP expression constructs, and subjected the cell lysates
to immunoprecipitation with either GFP or Par-4 antibodies. As
seen in Figure 3B, GRP78 coimmunoprecipitated with Par-4-
GFP (Figure 3B) when we used the Par-4 antibody with lysates
from Par-4-GFP transfectants. In coimmunoprecipitations using
Par-4 antibody and lysates from cells that were either untrans-
fected or transfected with GFP, we coimmunoprecipitated
GRP78 with endogenous Par-4. Likewise, when we used GFP
antibodies with lysates from the SAC-GFP transfectants,
GRP78 coimmunoprecipitated with SAC-GFP, whereas coim-
munoprecipitations using GFP antibodies with lysates from
either GFP-transfected cells or untransfected cells (as controls)
did not yield GRP78. These data indicate Par-4 antibody coim-
munoprecipitates endogenous Par-4 and ectopic Par-4-GFP
with endogenous GRP78, and GFP antibody coimmunoprecipi-
tates ectopic SAC-GFP with endogenous GRP78 (Figure 3B).
Accordingly, the SAC domain is sufficient for interactions with
GRP78.
As recent studies suggest cell surface GRP78 serves as
a receptor for soluble ligands to induce either apoptosis or
growth stimulation (Misra et al., 2002; Davidson et al., 2005;
Gonzalez-Gronow et al., 2006), we explored whether (1) Par-4
colocalizes with GRP78 at the plasma membrane, and (2) cell
surface GRP78 is essential for apoptosis by extracellular Par-4
and extracellular SAC. Treatment of PC-3 cells with TRAIL,
TRX-Par-4, and TRX-SAC, but not TRX, caused upregulation of
ER stress proteins GRP78 and CHOP/GADD153 (Figure S3A).
FACS analysis performed on PC-3 cells, which were not chemi-
cally fixed in order to allow detection of cell surface proteins,
indicated a significant increase (p < 0.001 by Student t test) in
GRP78 expression on the cell surface upon treatment with
TRAIL, TRX-Par-4, or TRX-SAC (Figures 3C and S3B). Similarly,
TRAIL treatment caused an increase in the expression of GRP78
andPar-4 protein in themembrane fraction, andGRP78 andPar-
4 were coimmunoprecipitated from this fraction (Figure S3F). To
further confirm the cell surface interaction of endogenous
GRP78 and Par-4, PC-3 cells were treated with TRAIL, then
intact cells were biotinylated to label cell surface proteins.
Whole-cell extracts were subjected to immunoprecipitation
with GRP78, Par-4, or PTEN control antibody, and biotinylated
proteins were detected with avidin-HRP. The GRP78 antibody,
as well as the Par-4 antibody, coimmunoprecipitated biotiny-
lated Par-4 and biotinylated GRP78 (Figure 3D). Moreover,
TRX-Par-4 but not TRX control protein, pulled-down biotinylated
GRP78 (Figure 3D). These findings support Par-4 binding GRP78
at the cell membrane.
To examine colocalization of Par-4 and GRP78, we exposed
PC-3 cells and BPH-1 cells (which do not respond to TRAIL;
see Figure S3A) to TRAIL or vehicle, then performed ICC analysis
for Par-4 and GRP78. As seen in Figure 3E, PC-3 and BPH-1
cells treated with vehicle showed colocalization of Par-4 andGRP78 in the ER. However, upon treatment with TRAIL, PC-3
cells showed membrane translocation of GRP78, whereas
BPH-1 cells retained GRP78 in the ER (Figure 3E). Notably, in
TRAIL-treated PC-3 cells, but not TRAIL-treated BPH-1 cells,
Par-4 colocalized with GRP78 at the plasma membrane (Figures
3E and S3E), indicating Par-4 colocalizes with GRP78 at the
plasma membrane in response to TRAIL exposure. We further
confirmedcolocalization ofGRP78andPar-4with theERmarker,
calnexin, and plasma membrane marker, Na+/K+-ATPase, in
PC-3 cells and BPH-1 treated with either TRAIL or vehicle
(Figure S3C).
GRP78 Cell Surface Interaction Is Essential
for Apoptosis by Extracellular Par-4
We next determined whether cell surface GRP78 is essential for
apoptosis by extracellular Par-4. PC-3 cells were pretreated with
GRP78 or control GST protein, subsequently treated with TRX-
Par-4, and finally scored for apoptotic cells. TRX-Par-4 induced
apoptosis in the presence of GST protein, but failed to induce
apoptosis in the presence of GRP78 protein (Figure 4A).
To further elucidate the interaction between extracellular Par-4
and cell surface GRP78, we preincubated PC-3 cells with
neutralizing antibodies against various regions of GRP78, and
then treated the cells with TRX-Par-4 or TRX. As seen in
Figure 4B, apoptosis induced by TRX-Par-4 was blocked by
the N-terminal-GRP78 antibody (NT-GRP78/N-20), but not by
antibodies (H-129 for amino acids 525-653, or CT-GRP78/
C-20) targeting the C terminus of GRP78. Similarly, in lung
cancer cells (H460) and cervical cancer cells (HeLa) apoptosis
by TRX-Par-4 was blocked by the N-terminal GRP78 antibody,
but not the C-terminal GRP78 antibodies (Figure S4A). These
findings indicate the N-terminal region of cell surface GRP78 is
essential for interaction with, and apoptosis by, extracellular
Par-4. Apoptosis induced by TRX-Par-4 or TRX-SAC was abro-
gated by preincubation of PC-3 cells with NT-GRP78 neutralizing
antibody, but not with several other antibodies (Figure 4C). Inter-
estingly, when PC-3 cells were transfected with Par-4-GFP,
SAC-GFP, or GFP constructs, and incubated with neutralizing
antibody for GRP78 (NT-GRP78), Par-4, or PTEN (control), anti-
body-mediated inhibition of cell surface GRP78 prevented extra-
cellular-Par-4 or -SAC from inducing apoptosis in the primary
transfectants and nontransfected cells (Figure S4C). In addition,
RNAi-mediated knock-down of GRP78 in PC-3 cells resulted in
diminished expression of GRP78, both in whole-cell lysates
and at the plasma membrane, and these cells were resistant to
apoptosis by TRX-Par-4 (Figure S5). Collectively, these results
suggest extracellular-Par-4 and -SAC induce apoptosis in PC-
3 cells (transfected or nontransfected) by a GRP78-dependent
mechanism.
Because we noted increased secretion of Par-4 by PC-3 cells
in response to TRAIL (Figure 2B), and because PC-3 cells, but
not BPH-1 cells, are sensitive to apoptosis induced by TRAIL
(Figure S3A), extracellular-Par-4, and extracellular-SAC (Fig-
ure 1D), we asked whether (1) extracellular-Par-4 is essential
for apoptosis by TRAIL, and (2) extracellular-Par-4/GRP78 inter-
action is required to induce apoptosis by TRAIL. PC-3 cells were
incubated with neutralizing antibody for GRP78, Par-4, or PTEN
(for control), and next treated with either TRAIL or vehicle. AsCell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc. 381
Figure 3. Par-4, via its SAC Domain, Binds to GRP78 and Colocalizes with GRP78 in the ER and at the Cell Membrane
(A) Par-4 binds to GRP78. Whole-cell extracts from PC-3 cells were subjected to immunoprecipitation (IP) with antibodies for Par-4, GRP78, or GFP, and the
immunoprecipitated complexes were resolved by SDS-PAGE and subjected to western blot (WB) analysis for GRP78 and Par-4. PC-3 whole-cell extracts
were used as input.
(B) Par-4 binds to GRP78 via its SAC domain. PC-3 cells were transfectedwith GFP, Par-4-GFP, or SAC-GFP expression constructs or left untransfected, and the
cell lysates were subjected to immunoprecipitation (IP) with Par-4 or GFP antibody. The immunoprecipitated complexes were subjected to western blot (WB)
analysis for GRP78 or GFP. Whole-cell extracts from the transfectants were used as input. Asterisks indicate breakdown products.
(C) Recombinant Par-4, SAC, and TRAIL individually increase GRP78 expression at the cell surface. PC-3 cells were treated with TRAIL (100 ng/ml), TRX-Par-4
(100 nM), TRX-SAC (100 nM), or TRX (250 nM) for various time intervals. The cells were collected after 6 hr (unfixed, so the antibody could detect only cell surface382 Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc.
seen in Figure 4D, TRAIL-inducible apoptosis was inhibited by
the Par-4 antibody, as well as by the GRP78 antibody, but not
by the PTEN antibody. These data imply secreted Par-4 and
cell surface GRP78 are requisite for TRAIL-induced apoptosis.
Given these in vitro observations, we explored Par-4 secretion
and biological activity in vivo. Our laboratory recently described
SAC-transgenic mice that are resistant to the growth of sponta-
neous tumors, whereas GFP-transgenic mice and littermate
control mice develop spontaneous tumors (Zhao et al., 2007).
By extension, Par-4 transgenic mice are also resistant to the
growth of spontaneous tumors (Table S2). The bone marrow
cells and serum of GFP- and Par-4-transgenic animals, as well
as littermate control mice, were tested for expression of GFP
and Par-4 protein. As seen in Figure 4E, the bone marrow cells
from the transgenic animals expressed GFP or Par-4-GFP, while
the serum from the Par-4-transgenic mice, but not from the GFP
and littermate control mice, contained detectable levels of Par-
4-GFP protein.
Next, we tested the biological activity of the serum from Par-4
transgenic mice against normal/immortalized cells and cancer
cell lines. The serum from Par-4-GFP-transgenic mice, but not
from GFP-transgenic mice and littermate control mice, induced
apoptosis in PC-3 cells, but not in BPH-1 cells (Figure 4E, bottom
left panel). To verify the apoptotic activity of the serum from the
Par-4-transgenicmicewas indeed due to the Par-4-GFP protein,
serum samples were pretreated with GFP or Par-4 antibody to
neutralize Par-4-GFP protein, or with GRP78 antibody to impede
binding of Par-4-GFP to cell surface GRP78, and applied to PC-3
cells in culture. As seen in Figure 4E (bottom right panel), GFP
and Par-4 antibodies, but not the control PTEN antibody, pre-
vented the serum from Par-4-GFPmice from inducing apoptosis
in the PC-3 cells. Significantly, GRP78 antibody also negated the
apoptotic effects of the serum from the Par-4-GFP mice
(Figure 4E, bottom right panel). These results indicate the Par-
4 protein is secreted in mice, and effects apoptosis via cell
surface GRP78 binding, thereby inhibiting the growth of tumor
cells.
Role of Intracellular Par-4 in Regulation of Apoptosis
by Extracellular Par-4
As intracellular Par-4 is essential for apoptosis in cancer cells
(Goswami et al., 2005), we investigated its role in the apoptotic
action of extracellular Par-4. In this effort, we knocked-down
the expression of endogenous Par-4 by RNA-interference, andthen exposed the cells to recombinant Par-4, SAC, or control
protein. Cells transfected with control siRNA underwent
apoptosis upon treatment with TRX-Par-4 or TRX-SAC, whereas
cells transfected with Par-4 siRNA did not (Figure 5A). Likewise,
endogenous Par-4 knock-down did not alter GRP78 levels in
GFP control protein treated cells, but inhibited induction of
GRP78 by TRX-Par-4 or TRX-SAC (Figure 5A). We conclude
endogenous Par-4 expression is essential for ER-stress depen-
dent induction ofGRP78 and for apoptosis by extracellular Par-4.
As cell surface GRP78 is essential for apoptosis induced by
extracellular Par-4, we sought to determine whether intracellular
Par-4 regulates GRP78 expression at the cell surface. PC-3 cells
were incubated with Par-4 or control siRNA duplexes, treated
with TRX or TRX-Par-4, and examined for cell surface GRP78
expression by FACS analysis. Knock-down of endogenous
Par-4 by siRNA resulted in severe reduction of cell surface
GRP78 expression (Figure 5B). However, total GRP78 protein
levels in the cell lysates were unaltered by Par-4 knock-down
(Figure 5B), implying that Par-4 was essential for trafficking
GRP78 to the plasma membrane.
Next, we restored expression of cell surface GRP78 by trans-
fecting the PC-3 cells with membrane-directed full-length
GRP78 (mGRP78) or its N-terminal mutant (mDN-GRP78;
lacking 66 amino acids at the N-terminus), following Par-4
knock down, and tested the cells for sensitivity to extracellular
Par-4. TRX-Par-4 induced apoptosis in cells transfected with
mGRP78, but not mDN-GRP78 (Figure 5C). Similar observations
were made in H460 cells and HeLa cells (Figures S6 and S7A).
We also tested immortalized BPH-1 cells, which do not respond
to extracellular Par-4, for apoptosis in response to extracellular
Par-4 after transfection with mGRP78 or mDN-GRP78. Cell
membrane-directed full-length mGRP78, but not mDN-GRP78,
rendered BPH-1 cells sensitive to apoptosis by TRX-Par-4
(Figure S7B). As expected, Par-4 binds to full-length mGRP78,
but not mDN-GRP78 (Figures S7C). Collectively, these findings
indicate intracellular Par-4 is essential for trafficking of GRP78
to the plasma membrane, and that extracellular Par-4 induces
apoptosis by binding to the N-terminal region of cell surface
GRP78.
DISCUSSION
We have uncovered a novel extracellular role for Par-4 protein.
Par-4 is spontaneously secreted by cultured cells in conditionedGRP78) and subjected to FACS analysis for GRP78. Mean values (+ standard deviation bars) of three separate experiments are shown. Asterisk (*) indicates the
difference is statistically significant (p < 0.001) by the Student’s t test.
(D) GRP78 binds Par-4 at the cell surface. Cells were treated with TRAIL (100 ng/ml) or vehicle for 6 h, and then labeled with cell-impermeable sulfo-NHS-LC-
biotin.Whole-cell extracts (WCE) of the TRAIL-treated/biotinylated sampleswere subjected to immunoprecipitation (IP) with the indicated antibodies (left panels).
For the pull-down of biotinylated GRP78 from TRAIL-treated cells, the corresponding WCE (10 mg) were incubated with polyhistidine-tagged recombinant
proteins TRX-Par-4 or TRX control (2 mg of each) for 2 h at 4C. Bound complexes were purified with metal affinity resin beads (middle panels). The immunopre-
cipitated proteins (left panels), bound complexes (middle panels), and also the corresponding WCE (indicated as ‘input’, right panels) were subjected to SDS-
PAGE, and blotted with avidin-HRP or with GRP78, Par-4, or TRX antibody. The 50 kDa band indicated by the asterisk is unidentified.
(E) Par-4 colocalizes with GRP78 in the ER and in the cell membrane. Cells were treated with TRAIL (100 ng/ml) or vehicle for 6 h, and subjected to ICC for Par-4
(green fluorescence), GRP78 (red fluorescence), and nuclei were revealed by DAPI (cyan fluorescence). White arrows show colocalization of Par-4 and GRP78 in
merged images (yellow fluorescence). A total of 400 cells were scored for colocalization of Par-4 and GRP78 at the cell membrane in each experiment, and mean
values (+ standard deviation bars) of three separate experiments are shown in the right panel. Asterisk (*) indicates the difference is statistically significant (p <
0.0001) by the Student’s t test. Magnification: For colocalization images- PC-3/TRAIL (200x); PC-3/vehicle (120x); and BPH-1 (80x); for all other BPH-1 images
(40x) and PC-3 images (80x).Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc. 383
Figure 4. Extracellular Par-4, SAC, and
TRAIL are Dependent on Cell Surface
GRP78 for Induction of Apoptosis
(A) Extracellular GRP78 neutralizes the apoptotic
action of TRX-Par-4. PC-3 cells were pretreated
with vehicle, GST, or GRP78 protein, and then
treated with TRX-Par-4, TRX protein, or vehicle.
After 24 hr, cells were subjected to ICC for active
caspase-3 (green fluorescence, see Figure S4B),
and apoptosis was quantified. The integrity of
the purified proteins was verified by SDS-PAGE
and Coomassie blue (CB) staining using protein
molecular weight markers (upper panel).
(B) Neutralizing antibody (NT-GRP78) directed
toward the N-terminal region of GRP78 inhibits
apoptosis by extracellular Par-4. Cells were prein-
cubated with the indicated antibodies for 30 min,
and then treated with TRX-Par-4 or TRX (100 nM
of each) for 24 hr. Apoptotic cells were scored by
ICC for active caspase-3.
(C) NT-GRP78-antibody neutralizes the apoptotic
action of exogenous Par-4 and SAC. Cells were
pretreated with PTEN, NT-GRP78, DR4, or DR5
antibody for 30 min, and then treated with TRX-
Par-4 (rPar-4), TRX-SAC (rSAC), or TRX. After
24 h, apoptosis was quantified by ICC for active
caspase-3.
(D) Par-4- and NT-GRP78-antibodies individually
neutralize the apoptotic action of TRAIL. PC-3
cells were pretreated with PTEN, NT-GRP78, or
Par-4 antibody, then treated with TRAIL (100 ng/
ml) or vehicle. After 24 h, apoptosis was quantified
by ICC for active caspase-3.
(E) Par-4, secreted in the serum of Par-4-trans-
genic mice, induces GRP78-mediated apoptosis
in PC-3 cells. Bone marrow cells from littermate
control, GFP-, and Par-4-GFP-transgenic mice
were analyzed by ICC for GFP (upper left panel),
and the serum from these mice was examined by
western blot for secreted Par-4 (upper right panel).
Loading was verified by CB staining for serum
albumin (upper right panel). Cells were treated
with the serum samples (20% final concentration)
either in the absence or presence of neutralizing
antibodies, and, after 24 h, apoptosis was quanti-
fied by ICC for active caspase-3 (lower panel).
In panels A-E, mean values (+ standard deviation
bars) of three separate experiments are shown.
Asterisk (*) indicates the difference is statistically
significant (p < 0.001) by the Student’s t test.medium, and Par-4 transgenic mice secrete Par-4 in their serum.
Spontaneous secretion of Par-4 was noted in both normal and
cancer cell cultures, and was further enhanced by exposure to
ER stress-producing agents, such as TG, TU, and TRAIL. Secre-
tion of Par-4 occurred by a BFA-sensitive pathway, and was not
dependent on apoptosis of the cells. Importantly, extracellular
Par-4 was functionally active, and bound to cell surface
GRP78 protein to induce apoptosis in cancer cells. The SAC
domain of Par-4 also interacts with GRP78, therefore implying
Par-4 binds to GRP78 independently of its carboxy-terminal
leucine zipper domain. Extracellular Par-4/SAC binding to cell
surface GRP78 produces a robust ER stress response loop
involving upregulation and trafficking of GRP78 to the cell384 Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc.membrane, in an intracellular Par-4-dependent manner (Fig-
ure 6). Moreover, extracellular Par-4 activates caspase-8 and
caspase-3 in a FADD-dependent manner (Figures S8A–S8E).
Consistent with a recent report suggesting ER-stress causes
activation of PERK (PKR-like ER kinase), a proximal component
of the ER stress pathway, which is known to activate FADD and
caspase-8 dependent apoptosis (Park et al., 2008), we noted
inhibition of PERK expression by RNAi led to inhibition of cas-
pase-8 dependent apoptosis by extracellular Par-4 and TRAIL
(Figure S8F). This extracellular function of Par-4/SAC constitutes
a paradigm shift in our interpretation of the mechanism of Par-4
action, and uncovers a broader therapeutic significance for this
cancer cell-selective apoptotic molecule.
Figure 5. Cell Membrane-Directed GRP78
Overrides the Effect of Intracellular Par-4
Knockdown and Restores Sensitivity to
TRX-Par-4
(A) Endogenous Par-4 expression is essential for
apoptosis by extracellular Par-4. PC-3 cells were
transfected with siRNA duplexes for Par-4 or
control siRNA. The cells were treated with TRX-
Par-4, TRX-SAC, or GFP protein for control for
24 hr, and apoptotic cells were scored by evalu-
ating active caspase-3 by ICC (upper panel).
Western blot analysis (lower panel) confirmed
both knock-down of Par-4 expression by siRNA
and its effect on GRP78 expression.
(B) Intracellular Par-4 regulates trafficking of cell
surface GRP78. PC-3 cells were transfected with
siRNA duplexes for Par-4 or control siRNA, treated
with TRX or TRX-Par-4, and processed as intact,
unfixed cells for expression of cell surface
GRP78 by FACS analysis (lower panel). Knock-
down of intracellular Par-4 by siRNA was
confirmed by western blot analysis of correspond-
ing whole-cell lysates (upper panel).
(C) Expression of membrane-targeted GRP78
restores sensitivity to TRX-Par-4 following intra-
cellular Par-4 knock-down. PC-3 cells were trans-
fected with siRNA duplexes for Par-4 or control
siRNA, and knock-down of intracellular Par-4
was confirmed as indicated in Panel B. The cells
were then transfected with vector, cell
membrane-directed full-length GRP78 (mGRP78),
or DN mutant of GRP78 (mDN-GRP78), and
expression of endogenous and ectopic GRP78 in
whole-cell lysates was confirmed by western blot
analysis (left panel inset). Finally, the transfectants
were subjected to treatment with TRX or TRX-Par-
4 for 24 h, and apoptotic cells were scored by eval-
uating active caspase-3 by ICC (left panel).
Expression of cell surface GRP78, as determined
by FACS analysis, is shown for Par-4 knock-
down cells transfected with the mGRP78
construct or vector and subsequently treated
with TRX-Par-4 (right panel). In panels A-C, mean
values (+ standard deviation bars) of three sepa-
rate experiments are shown. Asterisk (*) indicates
the difference is statistically significant (p <
0.001) by the Student’s t test.Secretion of Par-4
Our studies indicate intracellular Par-4 colocalizes with GRP78 in
the ER, and is secreted spontaneously via the classical BFA-
sensitivepathway involving theER/Golgi network. Par-4 secretion
is further enhanced by TG, TU, and TRAIL. Interestingly, all three
agents caused upregulation of GRP78 and CHOP/GADD153,
two key molecular indicators of ER stress/unfolded protein
response. Although TG and TU are known to produce ER stress
(Marchand et al., 2006), and 3,30-diindolylmethane induces
apoptosis by ER stress signaling via activation of caspase-8
and3 (Abdelrahim et al., 2006), the role of ER stress in the action
of TRAIL was not recognized previously. Similar to many other
proteins that are secreted into the extracellular environment,
Par-4doesnothavea readilydiscerniblesignalpeptidesequence.
Par-4 may, however, contain atypical short signal peptide
sequence(s), and this possibility is currently being investigated.Apoptotic Signaling via GRP78 Cell Surface Receptor
In this report we provide several lines of evidence to confirm
a physical and functional interaction between Par-4 and
GRP78 at the cell surface. These include: (1) Par-4 and GRP78
colocalize at the plasma membrane, as judged by ICC studies
using markers for the ER and plasma membrane; (2) Par-4 and
GRP78 coimmunoprecipitate from the membrane fraction using
either Par-4 or GRP78 antibody; (3) Par-4 and GRP78 were bioti-
nylated using cell-impermeable sulfo-NHS-LC-biotin, and coim-
munoprecipitated by Par-4 or GRP78 antibody; (4) neutralizing
antibodies against Par-4 or the N-terminus of GRP78 inhibit
apoptosis by TRAIL or Par-4 in intact cells; (5) RNAi-mediated
inhibition of Par-4 or GRP78 results in diminishedGRP78 expres-
sion at the cell surface and resistance to apoptosis by exogenous
Par-4; (6) cell membrane-directedGRP78 coimmunoprecipitates
with Par-4; and (g) cell membrane-directed GRP78 can restoreCell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc. 385
Figure 6. Model forApoptosisbyExtracellularPar-4
ER stress (a), induced by extracellular insults such as
TRAIL, causes translocation of the Par-4-GRP78 complex
from the ER to the plasma membrane (b). This leads to
elevated expression of GRP78 and Par-4 at the plasma
membrane (c), and secretion of Par-4 (d). Extracellular
Par-4 binds to cell surface GRP78 (e), and induces yet
more ER stress (f), thereby activating the loop for transloca-
tion of ER GRP78 to the plasma membrane, in an intracel-
lular Par-4-dependent manner. Finally, ER stress involves
upregulation of the ER component phospho-PERK, and
activation of caspase-8 in a PERK-dependent manner (g).
Activation of caspase-8 is also dependent on activation of
FADD. Collectively, these events lead to activation of cas-
pase-3 and apoptosis. This model is not restricted to pros-
tate cancer cells, as the key features were recapitulated in
lung and cervical cancer cells (Figure S11).sensitivity to exogenous Par-4. Collectively, these data demon-
strate Par-4 interacts with GRP78 at the cell surface.
GRP78 exists primarily as an ER protein with intracellular
chaperone functions, and is upregulated in response to ER
stress in order to diminish growth inhibitory signals, and promote
cell survival (Pootrakul et al., 2006; Lee, 2007). However, GRP78
is also expressed on the surface of most cancer cells and a few
nontransformed cells, and serves as a receptor for extracellular
ligands, such as alpha-2 macroglobulin (promotes cell prolifera-
tion) and Kringle 5 (induces apoptosis). It is also reported that
VDAC may serve as a coreceptor for Kringle 5-mediated
apoptosis of endothelial cells (Gonzalez-Gronow et al., 2006).
Also, synthetic peptides have been specifically designed to
bind cell surface GRP78, and induce apoptotic signaling (Arap
et al., 2004). Although Kringle 5 has been reported to induce cas-
pase-7 activation following GRP78 binding (Davidson et al.,
2005), extrinsic Par-4 and its SAC domain induce activation of
caspase-8 and 3, but not caspase-7 or 9 following cell
surface GRP78 binding (Figures S8 A–F and S9). This indicates
ligand-specific activation of distinct caspases prompts a similar
cellular outcome following binding to cell surface GRP78.
Consistent with the role of ER stress in the action of TRAIL and
exogenous Par-4, cancer cells (such as DU145) that are resistant
to apoptosis by TRAIL or exogenous Par-4 can be rendered
sensitive to the action of these proteins by bortezomib (Velcade),
which induces ER stress (Figure S10). We are currently investi-
gating the precise role of the ER components phospho-PERK
and phospho-eIF2Ea, which play a role in c-FLIP suppression
following CD95 activation (Park et al., 2008), in activation of
FADD and caspase-8 by exogenous TRAIL and Par-4. It is also
noteworthy that, unlike all of the previously described protein-
protein interactions of Par-4 that are mediated by its carboxy-
terminal leucine zipper domain, binding of Par-4 to GRP78 is
uniquely mediated by the SAC domain. Further deletion/muta-
tional analysis will uncover the specific residues or sub-domains
within the SAC sequence that promote binding and/or apoptotic
signaling.386 Cell 138, 377–388, July 24, 2009 ª2009 Elsevier Inc.Mutual Dependency of Extracellular and Intracellular
Par-4 for Induction of Apoptosis
In the present study, ectopic overexpression of Par-4 and SAC
induced apoptosis not only in transfected cells, but also in non-
transfected cells within the same cell culture. Apoptosis in the
transfected and nontransfected cells was inhibited by antibodies
targeting either extracellular Par-4 or GRP78, implying both
paracrine and autocrine effects for secreted Par-4. Consistently,
inhibition of intracellular Par-4 expression by RNAi negates cas-
pase 3 activation and apoptosis by extracellular Par-4. These
findings reveal a mutual dependency between extracellular and
intracellular Par-4 in activating apoptosis.
In contrast to intracellular GRP78, which may generally
serve anti-apoptotic functions (Lee, 2007), cell surface GRP78
promotes apoptosis by Par-4. Furthermore, intracellular Par-4
regulates the expression of GRP78 at the cell surface, as Par-4
knock-down does not alter total GRP78 levels in whole-cell
lysates, yet the amount of cell surface GRP78 is severely
down-modulated. As exogenous Par-4/SAC-inducible expres-
sion of GRP78 is inhibited upon knock-down of endogenous
Par-4, we infer inadequate GRP78 expression at the cell surface
precludes an ER stress-dependent increase in GRP78 in
response to exogenous Par-4/SAC. These results are consistent
with our observation that endogenous Par-4 is essential for cell
surface expression of GRP78.
Although both nontransformed and cancer cells express
GRP78 at the cell surface, only cancer cells exhibit ER stress
and apoptosis in response to extracellular Par-4. Par-4 binds
to the cell surface GRP78 molecules that are initially available
on cancer cells, thereby causing ER stress that further enhances
both translocation of GRP78 molecules to the cell surface and
apoptosis. Nontransformed cells neither respond to extracellular
Par-4 by ER stress, nor do they allow such trafficking of GRP78
to the cell surface. However, artificial overexpression of GRP78
at the cell membrane can promote apoptosis of the nontrans-
formed cells. Therefore, differential ER stress response may
contribute to the selective increase in cell surface trafficking of
GRP78, thus leading to Par-4-induced apoptosis in cancer cells
(also see Supplemental Discussion).
Similar to Par-4 and its SAC domain, TRAIL is known to selec-
tively induce apoptosis in cancer cells only. This study reveals
TRAIL causes secretion of Par-4, and that secreted Par-4 regu-
lates apoptosis by TRAIL. Consequently, inhibition of either
extracellular Par-4 or cell surface GRP78 impedes apoptosis
by TRAIL. Our results further reveal intracellular Par-4 is essential
for translocation of GRP78 from the ER to the cell surface in
response to TRAIL, thereby triggering the binding of Par-4 and
GRP78 at the cell surface to boost ER stress, and leading to acti-
vation of PERK and caspase-8. Inhibition of intracellular Par-4 by
RNAi blocked all of these responses, as well as apoptosis by
TRAIL (data not shown). These findings indicate extracellular
and intracellular Par-4 are both essential for apoptosis by TRAIL.
In summary, the present study identified a novel extrinsic
pathway for apoptosis by Par-4 acting via its SAC domain.
This pathway is essential for apoptosis by TRAIL, which, similar
to Par-4, induces cancer-specific apoptosis. The identification of
an extracellular role for Par-4 and SAC significantly broadens
their therapeutic potential for primary and metastatic tumors.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, Recombinant Proteins,
and Chemical Reagents
Human immortalized epithelial cells BPH-1, prostate cancer cells PC-3, lung
cancer cells H460, cervical cancer cells HeLa, human primary lung fibroblasts
HEL, human embryonic kidney cells HEK293, and mouse fibroblasts NIH 3T3
were from American Type Culture Collection, MD. The preparation of recombi-
nant proteins and plasmid constructs is detailed in Supplemental Experimental
Procedures.
The control siRNA and siRNA for Par-4 were from Dharmacon, Inc. and
SantaCruz Biotechnology, Inc. TRAIL was purchased from R. & D. Systems.
The antibodies for active caspases and ERK1/2 were from Cell Signaling,
Inc. The monoclonal antibody for b-actin, purified GRP78 protein, and BFA
were from Sigma Corp. All other antibodies (including those for GRP78)
were from SantaCruz Biotechnology, Inc. (Santa Cruz, CA). GRP78 antibodies
C-20, N-20, and H-129, were tested for inhibition of cell surface GRP78 inter-
action with Par-4; H-129 or 76-E6 was used for ICC and western blot analysis;
and H-129 was used for immunoprecipitation and FACS analysis.
Cell Surface Biotinylation
Cell surface proteins were biotinylated and visualized by treatment with avidin-
horseradishperoxidase (avidin-HRP)asdescribed in theSupplementalMethods.
GST-Pull-Down Assay, Coimmunoprecipitation, and Western Blot
Analysis
Purified GST (6 mg) or GST-Par-4 (3 mg) protein was incubated with glutathione
beads for 30 min, and subsequently washed and incubated with cell extracts
(10 mg) for 18 h at 4C. Protein eluted from the beads was resolved by SDS-
PAGE, and subjected to Coomassie blue staining and mass spectrometry at
the Protein Core Facility of the Columbia University Medical Center, NY.
Proteins were coimmunoprecipitated and detected by western blot analysis
as described (Goswami et al., 2005).
Immunocytochemistry, Apoptosis, and FACS Analysis
Immunocytochemical analysis and apoptosis procedures have been
described (Goswami et al., 2005). For fluorescence-activated cell sorting
(FACS) analysis, PC-3 cells were treated with recombinant proteins for 6 h
and then, without fixing them to allow detection of GRP78 at the cells surface,
the cells were subjected to FACS analysis using either GRP78 primary anti-body (H-129) or no primary antibody as control, and R-phytoerythrin-conju-
gated secondary antibody (from Invitrogen, Inc.).
Statistical Analysis
All experiments were performed in triplicate to verify the reproducibility of the
findings. Statistical analyses were carried out with Statistical Analysis System
software (SAS Institute, Cary, NC) and P values were calculated using the
Student t test.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Discussion, Supplemental Experi-
mental Procedures, Supplemental References, eleven figures, and two tables
and can be found with this article online at http://www.cell.com/supplemental/
S0092-8674(09)00579-0.
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